The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine

Haemophilus Influenzae Type b Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00197782
• Other study ID #: Hibboost
• Status: Completed
• Phase: Phase 4
• Start date: April 2003
• Est. completion date: December 2005

Study information

• Verified date: August 2018
• Source: Public Health England
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To measure the magnitude and persistence of the antibody response to a booster dose of Hib conjugate vaccine given between 9 months and 4 years of age to UK children who had completed primary immunisation with 3 doses of Hib vaccine given at 2/3/4 months of age either as a combined D/T/wholecellpertussis/Hib or D/T/acellularpertussis/Hib vaccine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: December 2005
• Est. primary completion date: December 2005
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 9 Months to 4 Years

Eligibility

Inclusion Criteria:

• Written informed consent from parent or legal guardian of the infant or child

• Age >= 9 months and <4 years at recruitment

• Eligible to receive a single dose of Hib vaccine as per the UK schedule

• Receipt of three doses of Hib vaccine in infancy

Exclusion Criteria:

• History of Hib infection

• History of severe local reaction that can be confidently related to a prior Hib immunisation

• Deferral of vaccination if acute illness and/or temperature >38C on day of vaccination

Related Conditions & MeSH terms

• Haemophilus Influenzae Type b

Intervention

Biological:
• Hib conjugate vaccine

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Public Health England

References & Publications (1)

Southern J, McVernon J, Gelb D, Andrews N, Morris R, Crowley-Luke A, Goldblatt D, Miller E. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who wer — View Citation